metformin and Epithelial Neoplasms
metformin has been researched along with Epithelial Neoplasms in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect." | 7.77 | Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. ( Beauchamp, MC; Gotlieb, WH; Piura, E; Pollak, M; Segal, E; Yasmeen, A, 2011) |
"When metformin was combined with carboplatin or paclitaxel, an increased apoptotic activity was observed, implicating a chemo-adjuvant potential." | 5.42 | Metformin and epithelial ovarian cancer therapeutics. ( Kumar, L; Patel, S; Singh, N, 2015) |
"The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect." | 3.77 | Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. ( Beauchamp, MC; Gotlieb, WH; Piura, E; Pollak, M; Segal, E; Yasmeen, A, 2011) |
"Metformin has been shown to act in synergy with certain anti-cancer agents, overcoming chemoresistance in various types of tumors." | 1.48 | Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines. ( Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG, 2018) |
"Metformin use was not associated with overall survival in the entire cohort (HR 0." | 1.46 | A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer. ( Balkrishnan, R; Camacho, F; Cantrell, LA; Garcia, C; Yao, A, 2017) |
"Low-grade serous ovarian cancer (LGSOC) constitutes 5-8% of epithelial ovarian cancers and is refractory to chemotherapy." | 1.46 | Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. ( Allo, G; Carey, MS; Chhina, J; Dai, J; Giri, S; Llaurado, M; Mert, I; Munkarah, AR; Rattan, R; Seward, S, 2017) |
"BRCA mutated ovarian cancers show increased responsiveness to PARP inhibitors." | 1.43 | Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. ( Al-Wahab, Z; Ali-Fehmi, R; Buekers, T; Chhina, J; Dar, S; Hijaz, M; Mert, I; Munkarah, AR; Rattan, R; Taylor, M, 2016) |
"When metformin was combined with carboplatin or paclitaxel, an increased apoptotic activity was observed, implicating a chemo-adjuvant potential." | 1.42 | Metformin and epithelial ovarian cancer therapeutics. ( Kumar, L; Patel, S; Singh, N, 2015) |
"The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen‑activated protein kinase (MAPK) inhibitor, on the sensitivity of cisplatin‑resistant ovarian cancer to cisplatin." | 1.40 | Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer. ( Guo, H; Ji, M; Peng, Z; Shi, H; Shi, M; Xie, Y, 2014) |
"This association is less clear in epithelial ovarian cancer (EOC)." | 1.40 | Diabetes mellitus and ovarian cancer: more complex than just increasing risk. ( Daily, LB; Erickson, BK; Fauci, JM; Haygood, CW; Leath, CA; Martin, JY; Matin, T; McGwin, G; Pasko, D; Shah, MM, 2014) |
Research
Studies (10)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 10 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Garcia, C | 1 |
Yao, A | 1 |
Camacho, F | 1 |
Balkrishnan, R | 1 |
Cantrell, LA | 1 |
Mert, I | 2 |
Chhina, J | 2 |
Allo, G | 1 |
Dai, J | 1 |
Seward, S | 1 |
Carey, MS | 1 |
Llaurado, M | 1 |
Giri, S | 2 |
Rattan, R | 3 |
Munkarah, AR | 2 |
Dos Santos Guimarães, I | 1 |
Ladislau-Magescky, T | 1 |
Tessarollo, NG | 1 |
Dos Santos, DZ | 1 |
Gimba, ERP | 1 |
Sternberg, C | 1 |
Silva, IV | 1 |
Rangel, LBA | 1 |
Holzgreve, H | 1 |
Xie, Y | 1 |
Peng, Z | 1 |
Shi, M | 1 |
Ji, M | 1 |
Guo, H | 1 |
Shi, H | 1 |
Shah, MM | 1 |
Erickson, BK | 1 |
Matin, T | 1 |
McGwin, G | 1 |
Martin, JY | 1 |
Daily, LB | 1 |
Pasko, D | 1 |
Haygood, CW | 1 |
Fauci, JM | 1 |
Leath, CA | 1 |
Patel, S | 1 |
Kumar, L | 1 |
Singh, N | 1 |
Hijaz, M | 1 |
Taylor, M | 1 |
Dar, S | 1 |
Al-Wahab, Z | 1 |
Ali-Fehmi, R | 1 |
Buekers, T | 1 |
Yasmeen, A | 1 |
Beauchamp, MC | 1 |
Piura, E | 1 |
Segal, E | 1 |
Pollak, M | 1 |
Gotlieb, WH | 1 |
Kumar, S | 1 |
Meuter, A | 1 |
Thapa, P | 1 |
Langstraat, C | 1 |
Chien, J | 1 |
Cliby, W | 1 |
Shridhar, V | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
10 other studies available for metformin and Epithelial Neoplasms
Article | Year |
---|---|
A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Cohort Studies; Female; Humans; Hypoglycemic | 2017 |
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Topics: AMP-Activated Protein Kinases; Antimetabolites; Blotting, Western; Carcinoma, Ovarian Epithelial; Ce | 2017 |
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferati | 2018 |
[Not Available].
Topics: Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplati | 2014 |
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
Topics: Adenocarcinoma, Papillary; Aged; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Comorbidity | 2014 |
Metformin and epithelial ovarian cancer therapeutics.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carb | 2015 |
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protei | 2016 |
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Car | 2011 |
Metformin intake is associated with better survival in ovarian cancer: a case-control study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cohort Studies; Di | 2013 |